Combogesic Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10532036 AFT PHARMS LTD Combination composition
Sep, 2025

(1 year, 2 months from now)

US11534407 AFT PHARMS LTD Pharmaceutical compostion containing acetominophen and ibuprofen
Feb, 2039

(14 years from now)

US11197830 AFT PHARMS LTD Pharmaceutical composition containing acetaminophen and ibuprofen
Feb, 2039

(14 years from now)

Combogesic is a drug owned by Aft Pharmaceuticals Ltd. It is used for treating mild to moderate acute pain in adults through a combination of acetaminophen and ibuprofen. Combogesic uses Acetaminophen; Ibuprofen as an active ingredient. Combogesic was launched by Aft Pharms Ltd in 2023. It is is available in tablet form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 27, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 01, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ACETAMINOPHEN; IBUPROFEN ingredient

Market Authorisation Date: 01 March, 2023

Treatment: A method of treating mild to moderate acute pain in adults by administering 975-1000 mg of acetaminophen and 292.5-300 mg of ibuprofen in a single administration

Dosage: TABLET

More Information on Dosage

COMBOGESIC family patents

Family Patents